Immunology of melanoma

Clinics in Dermatology

Volumn 31, Issue 2, 2013, Pages 156-165

  Mukherji, Bijay ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE; GANGLIOSIDE VACCINE; MELANOMA ANTIGEN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VACCINE;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL FEATURE; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INNATE IMMUNITY; MELANOMA SKIN CANCER; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SEROLOGY; TUMOR ESCAPE; TUMOR IMMUNOLOGY;

CYTOKINES; EPITOPES; HUMANS; IMMUNOTHERAPY; MELANOMA; MELANOMA-SPECIFIC ANTIGENS; SKIN NEOPLASMS; T-LYMPHOCYTES;

EID: 84874270249     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2012.08.017     Document Type: Article

References (48)

1. Mackensen A., Ferradini I., Carcelain I.G., et al. Evidence for in situ amplification of cytolytic T-lymphocytes with antitumor activity in a human regressing melanoma. Cancer Res 1993, 53:3569-3573.
2. Ferradini I., Mackensen A., Geneve C., et al. Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a regressive melanoma. J Clin Invest 1993, 91:1183-1190.
3. Mackensen A., Carcelain S., Viels S., et al. Direct evidence to support the immunosurveillance concept in a regressive melanoma. J Clin Invest 1994, 93:1397-1402.
4. Ehrlich P. Ueber den jeitzigne stand der karzinomforschung. Nederlandsch Tijdschrift voor Geneeskunde 2011, 5:273-290.
5. Klein G. Tumor antigens. Annu Rev Microbiol 1996, 20:223-252.
6. Hewitt H.B., Blake E.R., Walder A.S. A critique of the evidence for active host defense against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer 1976, 33:241-259.
7. Herberman R., Ortaldo J. Natural killer cells: their role in defense against disease. Science 1981, 214:24-29.
8. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989, 47:225-274.
9. Karre K. Natural killer cell recognition of missing self. Nat Immunol 2008, 9:477-480.
10. Lanier L.L. NK cell recognition. Annu Rev Immunol 2005, 23:225-274.
11. Moretta A., Bottino C., Marcenaro E., et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001, 19:197-223.
12. Carrega P., Pezzino G., Queirolo P. Susceptibility of human melanoma cells tom autologous natural killer (NK) cell killing: HLA-related effector mechanisms and role of unlicensed NK cells. PLoS One 2009, 4e8132.
13. Lozupone F., Pende D., Burgio V.L., et al. Effect of human natural killer and gamma delta T cells on the growth of human autologous melanoma xenografts in DCID mice. Cancer Res 2004, 64:378-385.
14. Old L.J. Cancer immunology: the search for specificity. G. H. A. Clowes Memorial lecture. Cancer Res 1981, 41:361-375.
15. Lloyd K.O., Old L.J. Human monoclonal antibodies to glycolipids and other carbohydrate antigens: dissection of the humoral immune response in cancer patients. Cancer Res 1989, 49:3441-3451.
16. Real F.X., Jules Mattes M., Houghton A., et al. Class 1 (Unique) tumor antigens of human melanoma. J Exp Med 1984, 160:1219-1233.
17. Pfreundscuh M. Exploitation of the B cell repertoire for the identification of human tumor antigens. Cancer Chemother Pharmacol 2000, 46:3-7.
18. Sahin U., Tureci O., Schmitt H., et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 1995, 92:11810-11813.
19. Hellstrom K.E., Hellstrom I. Cellular immunity against tumor antigens. Adv Cancer Res 1969, 12:167-214.
20. Rosenberg S.A., Spies P., Lafreniere R., et al. A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science 1986, 233:1318-1321.
21. Mukherji B., MacAllister T.J. Clonal analysis of cytotoxic T cell response against human melanoma. J Exp Med 1983, 158:240-245.
22. Knuth A., Danowski B., Oettgen H.F., et al. T cell mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin-2 dependent T cell cultures. Proc Natl Acad Sci U S A 1984, 81:3511-3515.
23. Kawakami Y., Suzuki Y., Shofuda T., et al. T cell immune responses against melanoma and melanocytes in cancer and autoimmunity. Pigment Cell Res 2000, 13:163-169.
24. Boon T., Coulie P.G., Van den Eynde B.J. Human T cell responses against melanoma. Annu Rev Immunol 2006, 24:175-208.
25. Mukherji B., Guha A., Chakraborty N.G., et al. Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma. J Exp Med 1989, 169:1961-1976.
26. Topalian S.L. MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy. Curr Opin Immunol 1994, 91:741-745.
27. Clay T.M., Custer M.C., Sachs J., et al. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confer antitumor reactivity. J Immunol 1999, 163:507-513.
28. Chhabra A., Yang P., Wang B., et al. CD4+CD25- T cells transduced to express MHC class-I restricted epitope specific TCR synthesize TH1 cytokines and exhibit class-I restricted cytolytic effector function in a human melanoma model. J Immunol 2008, 181:1063-1070.
29. Ray S., Chhabra A., Chakraborty N.G., et al. MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper response, in vitro. Clin Immunol 2011, 136:338-347.
30. Sensi M., Salvi S., Casteli C., et al. T cell receptor (TCR) structure of autologous melanoma reactive cytotoxic T lymphocytes (CTL) clones: tumor infiltrating lymphocytes over express in vivo the TCRβ chain sequence used by an HLA-A2-restricted and melanocyte lineage specific CTL clone. J Exp Med 1993, 178:1231-1246.
31. Shilyansky J., Nishimura M., Yanelli J., et al. T cell receptor usage by melanoma specific clonal and highly oligoclonal tumor infiltrating lymphocyte lines. Proc Natl Acad Sci U S A 1994, 91:2829-2833.
32. Irie R.F., Sze L.L., Saxton R.E. Human antibody to OFA-1, a tumor antigen produced in vitro by Epstein-Barr virus-transformed human B-lymphoblastoid cell lines. Proc Natl Acad Sci U S A 1982, 79:5666-5670.
33. Cahan L.D., Irie R.F., Sing R., et al. Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2. Proc Natl Acad Sci U S A 1982, 79:7629-7633.
34. Tsuchida T., Saxton R.E., Morton D.L., et al. Gangliosides of human melanoma. J Natl Cancer Inst 1987, 78:45-54.
35. Furukawa K, Lloyd KO. Gangliosides in melanoma. In: Ferrone S, editor. Human Melanoma: Immunology, Diagnostics, and Therapy. Heidelberg: Springer-Verlag; 1990. p. 15-30.
36. Livingston P.O. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol Rev 2006, 145:147-166.
37. Van der Bruggen P., Traversari C., Chomez P., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643-1647.
38. Kawakami Y., Rosenberg S.A. Human tumor antigens recognized by T cells. Immunol Rev 1997, 16:313-339.
39. Traversari C., Van der Bruggen P., Luescher I.F., et al. A nonapeptide encoded by human MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992, 176:1453-1457.
40. Hunt D.F., Henderson R.A., Shabanowitz J., et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992, 225:1261-1269.
41. Dunn G.P., Bruce A.T., Ikeda H., et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991-998.
42. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004, 22:531-549.
43. Nagaraj S., Grabrilovich D. Myeloid-derived suppressor cells. Adv Exp Med Biol 2007, 601:213-223.
44. Rabinovich G.A., Gabrilovich D., Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007, 5:267-296.
45. Ferrone S., Whiteside T.L. Tumor microenvironment and immune escape. Surg Oncol Clin N Am 2007, 16:755-774.
46. Mukherji B., Chakraborty N.G., Yamasaki S., et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci U S A 1995, 92:8079-8082.
47. Marchand M., van Baren N., Weynants P., et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE- 3 and presented by HLA-A1. Int J Cancer 1999, 80:219-230.
48. Rosenberg S.A., Restifo N.P., Yang J.C., et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008, 8:299-308.